Current treatment paradigms for advanced stage Hodgkin lymphoma

Longley, Jemma; Johnson, Peter

doi:10.1111/bjh.15622

Cited by 7 publications

(4 citation statements)

References 47 publications

(57 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The goal of future research on limited-stage Hodgkin lymphoma is to simultaneously maintain or increase long-term cure rates while reducing toxicity [30][31][32]. Intensified screening should be performed after the end of treatment.…”

Section: Discussionmentioning

confidence: 99%

Causes of death and effect of non-cancer-specific death on rates of overall survival in adult classic Hodgkin lymphoma: a populated-based competing risk analysis

Gao

Chen

et al. 2021

BMC Cancer

View full text Add to dashboard Cite

Background The improved prognosis of classic Hodgkin lymphoma (cHL) has been accompanied by elevated risks of non–cancer-specific death (non-CSD). The aim of this study was to verify the occurrence of non-CSD and its effect on rates of overall survival among adult patients with cHL. Methods To ensure sufficient follow-up time, we analyzed retrospective data from patients aged ≥20 years with cHL that was diagnosed between 1983 and 2005 in the Surveillance, Epidemiology, and End Results (SEER) database. Logistic regression was applied to analyze the non-CSD occurrence in relation to all factors. Using Fine-Gray’s method, we calculated the cumulative incidences of CSD and non-CSD. Stacked cumulative incidence plots and ratio of non-CSD to all causes of death were applied to evaluate the effect of non-CSD on rates of overall survival. Finally, we analyzed long-term mortality through Cox proportional hazard regression analysis and competing risk regression analysis to emphasize a more appropriate model of survival for patients with cHL. Results Among the 18,518 patients included, there were 3768 cases of CSD (20.3%) and 3217 of non-CSD (17.4%). Older age, earlier period, male sex, unmarried status, mixed cellularity (MC) and lymphocyte-depletion (LD) histological subtype, and patients received radiotherapy (RT) only were associated with more non-CSD according to binary logistic analysis. The cumulative incidence of non-CSD exceeded CSD after approximately 280 months follow-up. The most common causes of non-CSDs were cardiovascular disease, subsequent primary neoplasms, infectious diseases, accidents, and suicide. In a Cox proportional hazards model, patients who were black, unmarried, at an advanced stage or underwent chemotherapy (CT) alone were at greater risk of mortality than were white patients, who were married, at an early stage, and underwent combined modality; these populations were also found to be at greater risk for CSD in a competing risk model, but the risk of non-CSD did not differ significantly according to race and marital status, patients with early-stage disease and who underwent RT only were found to be at higher risk of non-CSD instead. Conclusions Lymphoma was the cause of death in most patients who died, but non-CSD was not unusual. Patients with cHL should be monitored closely for signs of cardiovascular disease and malignant tumors. Rates of overall survival of patients were diminished by non-CSD, and a competing risk model was more suitable for establishing the prognosis than was the Cox proportional hazards model.

show abstract

Section: Discussionmentioning

confidence: 99%

Causes of death and effect of non-cancer-specific death on rates of overall survival in adult classic Hodgkin lymphoma: a populated-based competing risk analysis

Gao

Chen

et al. 2021

BMC Cancer

View full text Add to dashboard Cite

show abstract

“…After a stage-adapted standardized first-line therapy (discussed in detail elsewhere) [ 52 , 79 , 80 , 81 ] up to 25% of patients may eventually experience refractoriness or disease relapse [ 52 ]. For these subjects, a second-line treatment should always be considered and optimized based on age, comorbidities and patient’s status.…”

Section: Management Of Relapsed/refractory Hodgkin Lymphomamentioning

confidence: 99%

Filling the Gap: The Immune Therapeutic Armamentarium for Relapsed/Refractory Hodgkin Lymphoma

Leroyer

Ziegler

Moulin

et al. 2022

JCM

View full text Add to dashboard Cite

Despite years of clinical progress which made Hodgkin lymphoma (HL) one of the most curable malignancies with conventional chemotherapy, refractoriness and recurrence may still affect up to 20–30% of patients. The revolution brought by the advent of immunotherapy in all kinds of neoplastic disorders is more than evident in this disease because anti-CD30 antibodies and checkpoint inhibitors have been able to rescue patients previously remaining without therapeutic options. Autologous hematopoietic cell transplantation still represents a significant step in the treatment algorithm for chemosensitive HL; however, the possibility to induce complete responses after allogeneic transplant procedures in patients receiving reduced-intensity conditioning regimens informs on its sensitivity to immunological control. Furthermore, the investigational application of adoptive T cell transfer therapies paves the way for future indications in this setting. Here, we seek to provide a fresh and up-to-date overview of the new immunotherapeutic agents dominating the scene of relapsed/refractory HL. In this optic, we will also review all the potential molecular mechanisms of tumor resistance, theoretically responsible for treatment failures, and we will discuss the place of allogeneic stem cell transplantation in the era of novel therapies.

show abstract

“…Patients with early-stage HL have an excellent 5-year overall survival and experience fewer treatment-related adverse effects, such as heart disease, infertility, and secondary malignancies, compared with patients with advanced stage HL. 24 If screening for sTARC results in a higher proportion of patients being diagnosed at an early stage, this will improve both outcome and quality of life. More important, sTARC levels can be measured by a relatively simple enzyme-linked immunosorbent assay, enabling economical and straightforward testing.…”

mentioning

confidence: 99%

Elevated serum TARC levels precede classic Hodgkin lymphoma diagnosis by several years

Diepstra,

Nolte,

van den Berg

et al. 2023

Blood

View full text Add to dashboard Cite

show abstract

Current treatment paradigms for advanced stage Hodgkin lymphoma

Cited by 7 publications

References 47 publications

Causes of death and effect of non-cancer-specific death on rates of overall survival in adult classic Hodgkin lymphoma: a populated-based competing risk analysis

Causes of death and effect of non-cancer-specific death on rates of overall survival in adult classic Hodgkin lymphoma: a populated-based competing risk analysis

Filling the Gap: The Immune Therapeutic Armamentarium for Relapsed/Refractory Hodgkin Lymphoma

Elevated serum TARC levels precede classic Hodgkin lymphoma diagnosis by several years

Contact Info

Product

Resources

About